Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid + hepatitis A vaccine
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tetanus toxoid + hepatitis A vaccine refers to the co-administration of two distinct vaccines in a clinical research setting, specifically evaluated by the National Institute of Allergy and Infectious Diseases (NIAID). Tetanus toxoid is an inactivated toxin (toxoid) derived from *Clostridium tetani*, designed to elicit protective antitoxin antibodies. The hepatitis A vaccine used in this context is an inactivated whole-virus vaccine intended to prevent infection by the hepatitis A virus (HAV). In the NIAID-sponsored study (NCT00001104), these vaccines were utilized as immunogenic probes to assess the functional recovery of the immune system in HIV-infected children and young adults following the initiation or modification of highly active antiretroviral therapy (HAART). The study aimed to determine if the quantitative increase in CD4+ T-cells observed during HAART translated into qualitative improvements in the response to both recall antigens (tetanus) and neoantigens (hepatitis A).
- Other names
- Tetanus toxoid and Hepatitis A Vaccine (Inactivated)Tetanus toxoid + Hepatitis A Vaccine
Beyond the preview
Go deeper on tetanus toxoid + hepatitis A vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid + hepatitis A vaccine.